ORLANDO, Fla.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) today announced that a controlled, randomized clinical trial using ACT’s myoblast therapy demonstrated marked improvement in heart failure symptoms after both six and twelve months. ACT had already published 6-month data for the trial. The positive 12-month results announced today demonstrate that the effects of ACT’s myoblast therapy persist for an extended period of time, an effect that has not been demonstrated for any other cellular therapy for heart disease. The trial also showed evidence that the hearts of the patients that received the therapy showed less cardiac remodeling (an increase in the size of the heart that signifies worsening of function) than did control patients. Principal investigator Dr. Nabil Dib, Director, Clinical Cardiovascular Cell Therapy, University of California, San Diego and Director of Cardiovascular Research at Chandler Regional Medical Center and Mercy Gilbert Medical Center, Phoenix, AZ, presented the results of the trial today in a Late Breaking Clinical Trial Session at the American Heart Association’s annual meeting in Orlando, Florida.
